News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 5.
News about: Primary CNS Lymphoma → cancer profile · × Clear filters
Drug-delivering particles aim to breach the blood–brain barrier
Nanoparticle- and exosome-based drug delivery platforms are advancing as strategies to overcome the blood–brain barrier, a decades-old obstacle to treating brain tumours and neurodegenerative diseases. Nature reviews competing approaches that aim to ferry therapeutics across the barrier selectively, potentially improving outcomes for gliomas and other CNS malignancies. No single technique has yet …
HCT-ASCT consolidation in primary CNS lymphoma: 3-year progression-free survival 78% versus 51% in the phase 3 MATRix/IELSG43 trial
A research highlight in Nature Reviews Clinical Oncology endorses high-dose chemotherapy with autologous stem-cell transplantation (HCT-ASCT) as consolidation after induction in eligible patients with primary central nervous system lymphoma. The underlying evidence is the randomised phase 3 MATRix/IELSG43 trial (Lancet 2026), in which 229 patients who had responded to induction were analysed: 3-ye…